Going forward, we may see more instances in which insurers deny or (temporarily) severely restrict coverage of accelerated ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...

Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from ...

Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has ...

Trump's pick for HHS secretary who endured confirmation hearings last week—has repeatedly criticized industry ties to the FDA ...

Securing FDA clearance or approval is a major accomplishment for medical device and pharmaceutical companies, but it’s not ...

Q4 2024 Earnings Call Transcript February 7, 2025 Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.12 ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

Arquitos returned 29.6% net of fees and expenses in 2024, compared to 25.0% for the S&P 500. Click here to read the full ...